PMID- 33758538
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220421
IS  - 1178-7090 (Print)
IS  - 1178-7090 (Electronic)
IS  - 1178-7090 (Linking)
VI  - 14
DP  - 2021
TI  - Effectiveness of Pregabalin Treatment for Neuropathic Pain in Patients with Spine 
      Diseases: A Pooled Analysis of Two Multicenter Observational Studies in Japan.
PG  - 757-771
LID - 10.2147/JPR.S293556 [doi]
AB  - PURPOSE: Neuropathic pain (NeP) is common among patients with chronic pain 
      associated with spine diseases. Practical effectiveness of pregabalin, one of the 
      first-line treatments for NeP, has not been evaluated in an entire population of 
      patients with spine diseases, including various pathophysiological conditions. 
      This pooled analysis aimed to evaluate the therapeutic value of pregabalin for 
      chronic pain with NeP component in patients with spine diseases in routine 
      primary care settings. PATIENTS AND METHODS: We pooled data from two 8-week 
      prospective observational cohort studies for patients with chronic low back pain 
      with accompanying lower limb pain (NeP component), and patients with chronic 
      cervical pain and accompanying upper limb radiating pain (NeP component) in 
      routine primary care settings in Japan. For both studies, patients were treated 
      for 8 weeks with pregabalin (alone/with other analgesics) or usual care with 
      conventional analgesics (eg, non-steroidal anti-inflammatory drugs). Changes in 
      pain numerical rating scale (NRS), Pain-Related Sleep Interference Scale (PRSIS), 
      and EuroQol 5-dimension 5-level (EQ-5D-5L) scores from baseline to week 8 were 
      summarized and compared between the pregabalin and usual care groups, and also 
      for subgroups of primary diagnosis. Safety was evaluated by adverse events (AEs) 
      in the pregabalin group. RESULTS: The pooled dataset comprised 700 patients 
      (pregabalin group: 302; usual care group: 398). All patient-reported outcomes 
      (PRO) scores significantly improved from baseline to week 8 in the pregabalin 
      than in the usual care group (NRS: P<0.0001; PRSIS: P<0.0001, and EQ-5D-5L: 
      P=0.0006). Overall, all three PRO measures showed greater improvement in the 
      pregabalin than in the usual care group, irrespective of the primary diagnosis. 
      AEs were reported in 36.1% of the pregabalin group. CONCLUSION: This analysis 
      suggested multi-faceted effectiveness of treatment with pregabalin from the 
      patient's perspectives under a "real-world" practice in all patients with chronic 
      NeP from various spine diseases.
CI  - (c) 2021 Taguchi et al.
FAU - Taguchi, Toshihiko
AU  - Taguchi T
AD  - Japan Organization of Occupational Health and Safety, Yamaguchi Rosai Hospital, 
      Sanyo-Onoda, Yamaguchi, Japan.
FAU - Nakano, Shogo
AU  - Nakano S
AD  - Pfizer Japan, Inc., Tokyo, Japan.
FAU - Nozawa, Kazutaka
AU  - Nozawa K
AD  - Pfizer Japan, Inc., Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210316
PL  - New Zealand
TA  - J Pain Res
JT  - Journal of pain research
JID - 101540514
PMC - PMC7981152
OTO - NOTNLM
OT  - chronic pain
OT  - neuropathic pain
OT  - pooled analysis
OT  - pregabalin
OT  - spine diseases
COIS- Shogo Nakano and Kazutaka Nozawa were employees of Pfizer Japan, Inc. at the time 
      of study conduct and manuscript development. Toshihiko Taguchi was not 
      financially compensated for their collaboration in this project or for the 
      development of this manuscript, although Toshihiko Taguchi has received 
      honorarium from Pfizer Japan Inc. outside of this work. The authors report no 
      other conflicts of interest relevant to this work.
EDAT- 2021/03/25 06:00
MHDA- 2021/03/25 06:01
PMCR- 2021/03/16
CRDT- 2021/03/24 06:44
PHST- 2020/11/27 00:00 [received]
PHST- 2021/02/18 00:00 [accepted]
PHST- 2021/03/24 06:44 [entrez]
PHST- 2021/03/25 06:00 [pubmed]
PHST- 2021/03/25 06:01 [medline]
PHST- 2021/03/16 00:00 [pmc-release]
AID - 293556 [pii]
AID - 10.2147/JPR.S293556 [doi]
PST - epublish
SO  - J Pain Res. 2021 Mar 16;14:757-771. doi: 10.2147/JPR.S293556. eCollection 2021.